DeepMed Research

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Certolizumab pegol

First Posted Date: 2021-02-05

Last Posted Date: 2024-02-12

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 33

Registration Number: NCT04740814

Locations: 🇺🇸
Ra0138 10025, Duncansville, Pennsylvania, United States
🇺🇸
Ra0138 1016, Memphis, Tennessee, United States
🇺🇸
Ra0138 1002, Covina, California, United States

and more 11 locations

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: bimekizumab

First Posted Date: 2021-01-22

Last Posted Date: 2025-03-24

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 41

Registration Number: NCT04718896

Locations: 🇵🇱
Ps0020 40334, Wroclaw, Poland
🇵🇱
Ps0020 40626, Bialystok, Poland
🇵🇱
Ps0020 40625, Lodz, Poland

and more 8 locations

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Phase 3

Active, not recruiting

Conditions: Epilepsy

Interventions: Drug: Brivaracetam

First Posted Date: 2021-01-20

Last Posted Date: 2025-05-16

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 70

Registration Number: NCT04715646

Locations: 🇯🇵
Ep0156 814, Shizuoka, Japan
🇺🇸
Ep0156 259, Hawthorne, New York, United States
🇺🇸
Ep0156 237, Durham, North Carolina, United States

and more 27 locations

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: Zampilimab
Drug: Placebo

First Posted Date: 2021-01-12

Last Posted Date: 2022-07-19

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 16

Registration Number: NCT04705350

Locations: 🇬🇧
Up0105 001, London, United Kingdom

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Recruiting

Conditions: Juvenile Absence Epilepsy
Childhood Absence Epilepsy

Interventions: Drug: Brivaracetam
Other: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2025-04-15

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 160

Registration Number: NCT04666610

Locations: 🇺🇸
N01269 116, Denver, Colorado, United States
🇺🇸
N01269 103, Loxahatchee Groves, Florida, United States
🇺🇸
N01269 111, Miami, Florida, United States

and more 50 locations

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Phase 2

Completed

Conditions: Early-stage Parkinson's Disease

Interventions: Drug: UCB0599
Drug: Placebo

First Posted Date: 2020-12-08

Last Posted Date: 2024-10-02

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 496

Registration Number: NCT04658186

Locations: 🇺🇸
Pd0053 50529, Baltimore, Maryland, United States
🇺🇸
Pd0053 50547, Baltimore, Maryland, United States
🇺🇸
Pd0053 50255, Columbus, Ohio, United States

and more 112 locations

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Phase 1

Active, not recruiting

Conditions: Progressive Supranuclear Palsy

Interventions: Drug: UCB0107 (bepranemab)

First Posted Date: 2020-12-08

Last Posted Date: 2025-02-17

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 19

Registration Number: NCT04658199

Locations: 🇧🇪
Psp002 40002, Leuven, Belgium
🇧🇪
Psp002 40122, Edegem, Belgium
🇩🇪
Psp002 40277, Bochum, Germany

and more 8 locations

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: UCB7853
Other: Placebo

First Posted Date: 2020-12-03

Last Posted Date: 2024-07-08

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 62

Registration Number: NCT04651153

Locations: 🇳🇱
Up0092 201, Leiden, Netherlands
🇬🇧
Up0092 101, London, United Kingdom

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Rozanolixizumab

First Posted Date: 2020-12-03

Last Posted Date: 2025-04-18

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 165

Registration Number: NCT04650854

Locations: 🇨🇳
Mg0007 20086, Taipei City, Taiwan
🇺🇸
Mg0007 50073, Tampa, Florida, United States
🇺🇸
Mg0007 50122, Miami, Florida, United States

and more 66 locations

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: UCB9741
Drug: Subcutaneous Placebo
Drug: Intravenous Placebo

First Posted Date: 2020-11-25

Last Posted Date: 2025-04-24

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 107

Registration Number: NCT04643457

Locations: 🇧🇬
Up0089 301, Sofia, Bulgaria
🇧🇬
Up0089 304, Sofia, Bulgaria
🇩🇪
Up0089 408, Heidelberg, Germany

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy